Effective March 10, 2023, we ask all patients and visitors to park in the East Garage while the West Garage is momentarily closed. We appreciate your understanding and apologize for any inconvenience this may cause.
Hypofractionation Lung Cancer
At Fox Chase Cancer Center, we believe delivering high quality clinical care should be convenient for our patients. Our radiation oncologists have worked to help pioneer an advanced treatment technique that is quickly becoming a standard of care for lung cancer patients.
It’s called hypofractionation.
Using hypofractionation, or hypofractionated radiation therapy, more doses of radiation are delivered per treatment, so patients can complete their course of radiation therapy much faster than conventional treatment and costs patients less money.
Hypofractionation can shave weeks off the traditional treatment length with the possibility of fewer short term side effects and a better quality of life for our patients. And, many clinical trials have proven hypofractionation to be just as safe and effective as conventional radiation therapy.
Though the length of treatment using hypofractionation depends on the cancer type being treated, lung cancer patients can complete their treatment course in as little as 1 ½ weeks when appropriate – compared to conventional treatment which typically takes 6 to 6 ½ weeks.
Many clinical trials have proven hypofractionation to be just as safe and effective as conventional radiation therapy.
Fox Chase researchers conducted one of the biggest studies of hypofractionation in the U.S. testing the current standard of radiation care administered over many weeks compared to hypofractionation delivered at higher doses in a shorter period of time.
The results, presented at ASTRO, found no statistically significant difference in long-term toxicity between the two techniques, and determined hypofractionation was well tolerated with very few side effects.
Share with Facebook
Share with twitter
Share with email